Insurance - Life
Compare Stocks
5 / 10Stock Comparison
UNM vs UNH vs CVS vs CI vs ELV
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
UNM vs UNH vs CVS vs CI vs ELV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Insurance - Life | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $12.97B | $335.60B | $111.40B | $74.85B | $80.98B |
| Revenue (TTM) | $13.30B | $449.71B | $407.90B | $277.94B | $200.41B |
| Net Income (TTM) | $781M | $12.04B | $2.93B | $6.29B | $5.24B |
| Gross Margin | 33.9% | 18.8% | 13.9% | 9.3% | 23.2% |
| Operating Margin | 7.5% | 4.2% | 1.5% | 3.4% | 3.8% |
| Forward P/E | 9.2x | 20.2x | 12.2x | 9.4x | 13.9x |
| Total Debt | $3.90B | $78.39B | $93.59B | $31.46B | $33.23B |
| Cash & Equiv. | $158M | $24.36B | $8.51B | $7.68B | $9.49B |
UNM vs UNH vs CVS vs CI vs ELV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Unum Group (UNM) | 100 | 530.1 | +430.1% |
| UnitedHealth Group … (UNH) | 100 | 121.3 | +21.3% |
| CVS Health Corporat… (CVS) | 100 | 133.2 | +33.2% |
| Cigna Corporation (CI) | 100 | 143.9 | +43.9% |
| Elevance Health Inc. (ELV) | 100 | 126.8 | +26.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: UNM vs UNH vs CVS vs CI vs ELV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
UNM is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 177.2% 10Y total return vs UNH's 220.6%
- Lower P/E (9.2x vs 12.2x)
- Combined ratio 0.9 vs CVS's 1.0 (lower = better underwriting)
UNH lags the leaders in this set but could rank higher in a more targeted comparison.
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.05, yield 3.1%
- Beta 0.05, yield 3.1%, current ratio 0.84x
- Beta 0.05 vs UNH's 0.59
- 3.1% yield, vs UNH's 2.4%
CI is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 0.35, Low D/E 75.1%, current ratio 0.85x
ELV ranks third and is worth considering specifically for growth exposure and valuation efficiency.
- Rev growth 12.6%, EPS growth -2.2%, 3Y rev CAGR 8.3%
- PEG 2.01 vs UNM's 4.76
- 12.6% revenue growth vs UNM's 2.1%
- 4.3% ROA vs CVS's 1.1%, ROIC 9.1% vs 5.0%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.6% revenue growth vs UNM's 2.1% | |
| Value | Lower P/E (9.2x vs 12.2x) | |
| Quality / Margins | Combined ratio 0.9 vs CVS's 1.0 (lower = better underwriting) | |
| Stability / Safety | Beta 0.05 vs UNH's 0.59 | |
| Dividends | 3.1% yield, vs UNH's 2.4% | |
| Momentum (1Y) | +34.7% vs CI's -13.3% | |
| Efficiency (ROA) | 4.3% ROA vs CVS's 1.1%, ROIC 9.1% vs 5.0% |
UNM vs UNH vs CVS vs CI vs ELV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
UNM vs UNH vs CVS vs CI vs ELV — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
UNM leads in 2 of 6 categories
CI leads 2 • CVS leads 1 • UNH leads 0 • ELV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
UNM leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 33.8x UNM's $13.3B. UNM is the more profitable business, keeping 5.9% of every revenue dollar as net income compared to CVS's 0.7%. On growth, UNM holds the edge at +9.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $13.3B | $449.7B | $407.9B | $277.9B | $200.4B |
| EBITDAEarnings before interest/tax | $1.1B | $23.2B | $10.5B | $12.1B | $8.9B |
| Net IncomeAfter-tax profit | $781M | $12.0B | $2.9B | $6.3B | $5.2B |
| Free Cash FlowCash after capex | $539M | $19.7B | $7.4B | $7.7B | $6.5B |
| Gross MarginGross profit ÷ Revenue | +33.9% | +18.8% | +13.9% | +9.3% | +23.2% |
| Operating MarginEBIT ÷ Revenue | +7.5% | +4.2% | +1.5% | +3.4% | +3.8% |
| Net MarginNet income ÷ Revenue | +5.9% | +2.7% | +0.7% | +2.3% | +2.6% |
| FCF MarginFCF ÷ Revenue | +4.1% | +4.4% | +1.8% | +2.8% | +3.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +9.0% | +2.0% | +6.2% | +4.6% | +2.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +33.0% | +0.7% | +63.1% | +29.1% | -16.8% |
Valuation Metrics
CI leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 12.8x trailing earnings, CI trades at a 80% valuation discount to CVS's 62.8x P/E. Adjusting for growth (PEG ratio), ELV offers better value at 2.15x vs UNM's 9.73x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $13.0B | $335.6B | $111.4B | $74.9B | $81.0B |
| Enterprise ValueMkt cap + debt − cash | $16.7B | $389.6B | $196.5B | $98.6B | $104.7B |
| Trailing P/EPrice ÷ TTM EPS | 18.76x | 27.95x | 62.81x | 12.81x | 14.84x |
| Forward P/EPrice ÷ next-FY EPS est. | 9.18x | 20.19x | 12.19x | 9.36x | 13.93x |
| PEG RatioP/E ÷ EPS growth rate | 9.73x | — | — | — | 2.15x |
| EV / EBITDAEnterprise value multiple | 15.82x | 16.70x | 13.11x | 8.39x | 10.84x |
| Price / SalesMarket cap ÷ Revenue | 0.99x | 0.75x | 0.28x | 0.27x | 0.41x |
| Price / BookPrice ÷ Book value/share | 1.25x | 3.31x | 1.47x | 1.80x | 1.88x |
| Price / FCFMarket cap ÷ FCF | 23.35x | 20.88x | 14.27x | 8.92x | 25.51x |
Profitability & Efficiency
CI leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for CVS. UNM carries lower financial leverage with a 0.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +7.1% | +11.5% | +3.9% | +15.1% | +11.9% |
| ROA (TTM)Return on assets | +1.6% | +3.9% | +1.1% | +4.1% | +4.3% |
| ROICReturn on invested capital | +4.7% | +9.2% | +5.0% | +10.4% | +9.1% |
| ROCEReturn on capital employed | +1.5% | +9.7% | +6.1% | +9.2% | +8.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 6 | 5 | 8 | 6 |
| Debt / EquityFinancial leverage | 0.35x | 0.77x | 1.24x | 0.75x | 0.75x |
| Net DebtTotal debt minus cash | $3.7B | $54.0B | $85.1B | $23.8B | $23.7B |
| Cash & Equiv.Liquid assets | $158M | $24.4B | $8.5B | $7.7B | $9.5B |
| Total DebtShort + long-term debt | $3.9B | $78.4B | $93.6B | $31.5B | $33.2B |
| Interest CoverageEBIT ÷ Interest expense | 5.48x | 4.71x | 2.11x | 6.77x | 5.39x |
Total Returns (Dividends Reinvested)
UNM leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in UNM five years ago would be worth $29,376 today (with dividends reinvested), compared to $9,743 for UNH. Over the past 12 months, CVS leads with a +34.7% total return vs CI's -13.3%. The 3-year compound annual growth rate (CAGR) favors UNM at 24.0% vs UNH's -7.1% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +5.2% | +10.6% | +10.6% | +2.3% | +5.8% |
| 1-Year ReturnPast 12 months | +2.0% | -3.2% | +34.7% | -13.3% | -9.0% |
| 3-Year ReturnCumulative with dividends | +90.5% | -19.9% | +36.6% | +13.6% | -15.6% |
| 5-Year ReturnCumulative with dividends | +193.8% | -2.6% | +17.0% | +18.5% | +1.5% |
| 10-Year ReturnCumulative with dividends | +177.2% | +220.6% | +3.5% | +136.5% | +202.1% |
| CAGR (3Y)Annualised 3-year return | +24.0% | -7.1% | +11.0% | +4.4% | -5.5% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.05 beta — it tends to amplify market swings less than UNH's 0.59 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs CI's 83.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.48x | 0.59x | 0.05x | 0.35x | 0.46x |
| 52-Week HighHighest price in past year | $83.13 | $395.52 | $88.63 | $338.89 | $424.24 |
| 52-Week LowLowest price in past year | $68.28 | $234.60 | $58.35 | $239.51 | $273.71 |
| % of 52W HighCurrent price vs 52-week peak | +96.6% | +93.5% | +98.5% | +83.8% | +87.9% |
| RSI (14)Momentum oscillator 0–100 | 61.0 | 75.9 | 69.3 | 53.5 | 75.5 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 7.9M | 7.4M | 1.5M | 1.9M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: UNM as "Hold", UNH as "Buy", CVS as "Buy", CI as "Buy", ELV as "Buy". Consensus price targets imply 22.0% upside for UNM (target: $98) vs 2.5% for ELV (target: $382). For income investors, CVS offers the higher dividend yield at 3.06% vs ELV's 1.85%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $98.00 | $385.43 | $95.20 | $328.00 | $382.38 |
| # AnalystsCovering analysts | 30 | 52 | 41 | 39 | 37 |
| Dividend YieldAnnual dividend ÷ price | +2.2% | +2.4% | +3.1% | +2.1% | +1.8% |
| Dividend StreakConsecutive years of raises | 20 | 25 | 0 | 6 | 15 |
| Dividend / ShareAnnual DPS | $1.77 | $8.70 | $2.67 | $6.06 | $6.89 |
| Buyback YieldShare repurchases ÷ mkt cap | +7.8% | +1.7% | 0.0% | +4.8% | +3.2% |
UNM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CI leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
UNM vs UNH vs CVS vs CI vs ELV: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is UNM or UNH or CVS or CI or ELV a better buy right now?
For growth investors, Elevance Health Inc.
(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus 2. 1% for Unum Group (UNM). Cigna Corporation (CI) offers the better valuation at 12. 8x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — UNM or UNH or CVS or CI or ELV?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 12.
8x versus CVS Health Corporation at 62. 8x. On forward P/E, Unum Group is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Elevance Health Inc. wins at 2. 01x versus Unum Group's 4. 76x.
03Which is the better long-term investment — UNM or UNH or CVS or CI or ELV?
Over the past 5 years, Unum Group (UNM) delivered a total return of +193.
8%, compared to -2. 6% for UnitedHealth Group Incorporated (UNH). Over 10 years, the gap is even starker: UNH returned +220. 6% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — UNM or UNH or CVS or CI or ELV?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
05β versus UnitedHealth Group Incorporated's 0. 59β — meaning UNH is approximately 1059% more volatile than CVS relative to the S&P 500. On balance sheet safety, Unum Group (UNM) carries a lower debt/equity ratio of 35% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — UNM or UNH or CVS or CI or ELV?
By revenue growth (latest reported year), Elevance Health Inc.
(ELV) is pulling ahead at 12. 6% versus 2. 1% for Unum Group (UNM). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, CI leads at 15. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — UNM or UNH or CVS or CI or ELV?
Unum Group (UNM) is the more profitable company, earning 5.
7% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 5. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UNM leads at 7. 2% versus 2. 6% for CVS. At the gross margin level — before operating expenses — UNM leads at 38. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is UNM or UNH or CVS or CI or ELV more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Elevance Health Inc. (ELV) is the more undervalued stock at a PEG of 2. 01x versus Unum Group's 4. 76x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Unum Group (UNM) trades at 9. 2x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 11. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for UNM: 22. 0% to $98. 00.
08Which pays a better dividend — UNM or UNH or CVS or CI or ELV?
All stocks in this comparison pay dividends.
CVS Health Corporation (CVS) offers the highest yield at 3. 1%, versus 1. 8% for Elevance Health Inc. (ELV).
09Is UNM or UNH or CVS or CI or ELV better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
05), 3. 1% yield). Both have compounded well over 10 years (CVS: +3. 5%, UNH: +220. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between UNM and UNH and CVS and CI and ELV?
These companies operate in different sectors (UNM (Financial Services) and UNH (Healthcare) and CVS (Healthcare) and CI (Healthcare) and ELV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: UNM is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; CI is a mid-cap deep-value stock; ELV is a mid-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.